<DOC>
	<DOCNO>NCT02232971</DOCNO>
	<brief_summary>Background : Patients type 1 diabetes ( T1D ) need lifelong supply external insulin advise aim near-normalization blood glucose level intensive insulin therapy . We propose new approach achieve treatment goal T1D : combine use insulin glucagon , i.e . dual-hormone treatment.Only recently prospect treating patient soluble glucagon arisen thus study low dose glucagon treatment mild hypoglycemia need determine whether clinical rationale dual-hormone treatment T1D . Aim : The purpose clinical study investigate glycemic response subcutaneous glucagon administration mild hypoglycemia T1D patient treat insulin pump . Different glucagon dos apply determine appropriate dose future dual-hormone treatment T1D . Methods : A clinical , randomize , single blind , crossover study conduct . Eight T1D patient treat insulin pump study four day . All patient good metabolic control ( HbA1c &lt; 7.5 % ) , C-peptide negative hypoglycemia awareness . On study day , hypoglycemia induce subcutaneously insulin afterward treat single subcutaneous dose glucagon . The study procedures identical day except administer dose glucagon ( day 1 : placebo , day 2 : 100 ug , day 3 : 200 ug , day 4 : 300 ug ) . All patient blind glucagon dose carry four day random order . Endpoints : The present study focus primarily dose related plasma glucose response glucagon ; secondary duration hyperglycemic effect glucagon tertiary glucagon effect catecholamine , cortisol , growth hormone , free fatty acid triglyceride . The study conduct august 2014 .</brief_summary>
	<brief_title>Treatment Low Blood Sugar With Glucagon Among Patients With Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Glucagon</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<criteria>Males female age 1865 year Diagnosed type 1 diabetes &gt; 3 year HbA1c &lt; 58 mmol/mol No appearance autonome neuropathy Body mass index ( BMI ) 2025 kg/m2 Remained hypoglycemic awareness Insulin pump treatment &gt; 1 year Allergic glucagon lactose Pregnancy , breastfeeding , intention become pregnant , use adequate contraception Any disease condition would interfere subject 's safety Use medication significantly impact glucose metabolism</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>glucagon</keyword>
	<keyword>insulin pump</keyword>
	<keyword>artificial pancreas</keyword>
	<keyword>closed-loop</keyword>
</DOC>